BriaCell Therapeutics Bolsa (NASDAQ: BCTX)

Últimas noticias sobre BriaCell Therapeutics (NASDAQ:BCTX) Bolsa

BriaCell Therapeutics

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics Corp

Jefferies analyst Sheila Kahyaoglu downgrades General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) from Buy to Hold and lowers the price target from $345 to $300.

News

Downgrades

Price Target

Analyst Ratings

Jefferies Downgrades General Dynamics to Hold, Lowers Price Target to $300

WIIM

Cleveland Cliffs shares are trading lower. Morgan Stanley forecasted the companies Q4 EBITDA 97% lower than its previous estimate.

Western Digital shares are trading lower following the company's presentation at the Barclays 22nd Annual Global Technology Conference.

Evercore ISI Group analyst Michael Binetti maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Outperform and raises the price target from $26 to $30.

Evercore ISI Group Maintains Outperform on Amer Sports, Raises Price Target to $30

180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.

ATNF

Reported Earlier, 180 Life Sciences Regains Full Compliance With Nasdaq Listing Standards

Events

Trading Ideas

AMD To Present At The Barclays 22nd Annual Global Technology Conference At 2:00 pm ET

Kroger Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) disclosed the termination of its merger agreement with Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) following a preliminary injunction by the U.S. District <a href="https://www.benzinga.com/24/12/42456428/kroger-and-albertsons-call-off-merger-plans-75-billion-share-buyback-cancels-47-billion-merger-debt">Court in Oregon</a>.
Kroger's Board approved a new $7.5 billion share repurchase program, replacing the previous $1 billion authorization from September 2022.
The company plans to execute an accelerated share repurchase (ASR) agreement for about $5 billion of common stock. Kroger anticipates strong free cash flow and remains focused on capital allocation priorities. Following the termination of the merger agreement, Kroger will redeem $4.7 billion in senior notes issued on August 27, 2024.
Kroger shares gained 3.1% to trade at $63.20 on Thursday.
These analysts made changes to their price targets on Kroger following the announcement.
<ul>
<li>Wells Fargo analyst Edward Kelly maintained Kroger with an Overweight and raised the price target from $70 to $73.</li>
<li>BMO Capital analyst Kelly Bania maintained the stock with a Market Perform and raised the price target from $60 to $63.</li>
<li>UBS analyst Michael Lasser maintained Kroger with a Neutral and raised the price target from $63 to $66. </li>
</ul>
Considering buying KR stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12131735/image-106-1024x572.png" alt="" class="wp-image-690044" style="width:711px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12131735/image-106-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12131735/image-106-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12131735/image-106-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12131735/image-106.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

Markets

These Analysts Boost Their Forecasts On Kroger

Blynk, the leading Low-Code IoT SaaS platform, has partnered with Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), a leading provider of global voice and data satellite communications, in support of the new <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4324115-1&amp;h=1873876177&amp;u=https%3A%2F%2Fwww.iridium.com%2Fproducts%2Fcertus-9704-satellite-iot-developer-kit%2F&amp;a=Iridium+Certus%E2%84%A2+9704+Development+Kit">Iridium Certus&#x2122; 9704 Development Kit</a>, an end-to-end product evaluation tool for the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4324115-1&amp;h=1173891138&amp;u=https%3A%2F%2Fwww.iridium.com%2Fproducts%2Fcertus-9704-module%2F&amp;a=Iridium+Certus+9704+module">Iridium Certus 9704 module</a>. This partnership allows engineering teams to jumpstart their projects with Iridium's new hardware using Blynk's powerful IoT platform, creating an ideal environment both for discovery and development of new Iridium satellite-based solutions.
Blynk Selected as Iridium's Software Partner for New Satellite IoT Development Kit, Simplifying Global Connectivity
The Iridium Certus&#x2122; 9704 Development Kit features the cutting-edge Iridium Certus 9704 IoT Transceiver, designed to enable reliable, truly global connectivity, even in the most remote locations. Blynk's comprehensive IoT software suite empowers businesses to create, deploy, and scale satellite-enabled IoT solutions with unmatched ease. Offering a complete, out-of-the-box environment, Blynk supports every stage of IoT deployment—from minimum viable products (MVPs) to enterprise-grade solutions—eliminating the need for migration in-between.
Blynk partnered with Iridium to develop customizable IoT blueprints tailored specifically for the Iridium Certus 9704 Development Kit, enabling engineering teams to accelerate their projects with ready-to-use templates. These blueprints are complete with ready-to-upload firmware, as well as customizable mobile and web dashboards, reducing the time to create, test, and deploy satellite-based IoT solutions.

IRDM

Iridium Communications Partners With Blynk In Support Of The New Iridium Certus 9704 Development Kit, An End-o-End Product Evaluation Tool For The Iridium Certus 9704 Module

Deep-pocketed investors have adopted a bullish approach towards Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Applied Mat. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 41% bearish. Among these notable options, 7 are puts, totaling $253,664, and 5 are calls, amounting to $207,742.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $210.0 for Applied Mat, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Applied Mat's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Applied Mat's significant trades, within a strike price range of $70.0 to $210.0, over the past month.
<h3>Applied Mat Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734027432_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$9.8</td>
<td>$9.35</td>
<td>$9.49</td>
<td>$180.00</td>
<td>$57.0K</td>
<td align="right">535</td>
<td align="right">121</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.2</td>
<td>$8.85</td>
<td>$9.2</td>
<td>$180.00</td>
<td>$55.2K</td>
<td align="right">535</td>
<td align="right">1</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$26.6</td>
<td>$26.1</td>
<td>$26.1</td>
<td>$195.00</td>
<td>$49.5K</td>
<td align="right">0</td>
<td align="right">19</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.55</td>
<td>$39.2</td>
<td>$40.25</td>
<td>$210.00</td>
<td>$40.2K</td>
<td align="right">319</td>
<td align="right">0</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.2</td>
<td>$9.45</td>
<td>$9.77</td>
<td>$195.00</td>
<td>$38.1K</td>
<td align="right">304</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Following our analysis of the options activities associated with Applied Mat, we pivot to a closer look at the company's own performance.
<h3>Where Is Applied Mat Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,920,877, the price of AMAT is down by -1.23%, reaching $169.03.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 63 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Applied Mat</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $221.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Applied Mat, which currently sits at a price target of $210. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Applied Mat with a target price of $225. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Applied Mat, maintaining a target price of $220. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $250. 
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Hold rating on Applied Mat with a target price of $200. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Applied Mat with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

AMAT

Looking At Applied Mat's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XOM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Exxon Mobil. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 55% bearish. Among these notable options, 3 are puts, totaling $101,760, and 6 are calls, amounting to $681,031.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $120.0 for Exxon Mobil, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Exxon Mobil's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Exxon Mobil's whale trades within a strike price range from $95.0 to $120.0 in the last 30 days. 
<h3>Exxon Mobil Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734027427_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$2.8</td>
<td>$2.64</td>
<td>$2.8</td>
<td>$109.00</td>
<td>$275.3K</td>
<td>3.4K</td>
<td>1.6K</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$2.94</td>
<td>$2.52</td>
<td>$2.8</td>
<td>$109.00</td>
<td>$168.0K</td>
<td>3.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$2.8</td>
<td>$2.68</td>
<td>$2.8</td>
<td>$109.00</td>
<td>$112.0K</td>
<td>3.4K</td>
<td>605</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$2.53</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$109.00</td>
<td>$50.0K</td>
<td>3.4K</td>
<td>2.4K</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.56</td>
<td>$1.45</td>
<td>$1.45</td>
<td>$111.00</td>
<td>$43.5K</td>
<td>142</td>
<td>318</td>
</tr>
</tbody>
</table>

<h3>About Exxon Mobil</h3>
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners with a total global refining capacity of 4.5 million barrels of oil per day and is one of the world's largest manufacturers of commodity and specialty chemicals.
In light of the recent options history for Exxon Mobil, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Exxon Mobil</h3>
<ul>
<li>With a trading volume of 6,181,601, the price of XOM is up by 0.15%, reaching $112.09.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Exxon Mobil</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $127.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Exxon Mobil, maintaining a target price of $115. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $115. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Exxon Mobil, which currently sits at a price target of $147. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Exxon Mobil, which currently sits at a price target of $132. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Exxon Mobil with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Exxon Mobil Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SMCI, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 39 uncommon options trades for Super Micro Computer.
This isn't normal.
The overall sentiment of these big-money traders is split between 43% bullish and 38%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $783,225, and 27 are calls, for a total amount of $2,273,532.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $24.0 to $75.0 for Super Micro Computer during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Super Micro Computer's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Super Micro Computer's whale activity within a strike price range from $24.0 to $75.0 in the last 30 days. 
<h3>Super Micro Computer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734027422_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.25</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$50.00</td>
<td>$417.0K</td>
<td>16.7K</td>
<td>46</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$1.68</td>
<td>$1.63</td>
<td>$1.68</td>
<td>$50.00</td>
<td>$251.7K</td>
<td>1.3K</td>
<td>4.2K</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$12.05</td>
<td>$11.95</td>
<td>$12.0</td>
<td>$42.00</td>
<td>$240.0K</td>
<td>180</td>
<td>201</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.17</td>
<td>$2.13</td>
<td>$2.17</td>
<td>$50.00</td>
<td>$217.1K</td>
<td>32.1K</td>
<td>1.4K</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$35.00</td>
<td>$144.8K</td>
<td>16.9K</td>
<td>79</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
After a thorough review of the options trading surrounding Super Micro Computer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Super Micro Computer's Current Market Status</h3>
<ul>
<li>With a trading volume of 28,699,566, the price of SMCI is down by -0.8%, reaching $37.98.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 12 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Super Micro Computer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

SMCI

Market Whales and Their Recent Bets on SMCI Options

Veritone and CBS News strengthen longstanding partnership, expanding AI-driven content licensing and distribution across national and local platforms
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveritone.me%2F3WkUewH&amp;esheet=54166189&amp;newsitemid=20241212462218&amp;lan=en-US&amp;anchor=Veritone%2C+Inc&amp;index=1&amp;md5=f1d10bf7a01d91364f36b3aa8a9cbb2c">Veritone, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>), a leader in building human-centered enterprise AI solutions, today announced the renewal of its longstanding exclusive global licensing agreement with CBS News. The multi-year contract renewal solidifies Veritone's position as a premier provider of content licensing solutions for broadcast networks and expands the partnership to include exclusive local news content from CBS Owned Stations.

PARA

VERI

Veritone Renews And Expands Multi-Year Exclusive Global Licensing Agreement With CBS News And Stations

Shaquille O'Neal is no <a href="https://www.benzinga.com/personal-finance/24/10/41305175/nba-legend-shaq-says-you-should-save-75-of-your-paycheck-its-not-about-how-much-you-make-its-abo">stranger to making tough business decisions</a>, but his explanation for selling his 17 Auntie Anne's franchises might be one of his most memorable.&nbsp;
During an appearance on the Earn Your Leisure podcast in 2021, the basketball legend turned entrepreneur didn't sugarcoat his reasoning: "I sold my Auntie Anne's because Black people don't like pretzels that much. So I had to switch it up."&nbsp;
One host jumped in, saying, "We eat the cinnamon ones," the other quickly backed him up with, "Yeah, yeah, yeah."
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>
But Shaq wasn't having it. He shot back, "Nobody eats no cinnamon pretzels." The crowd lost it, erupting in laughter.&nbsp;
It's classic Shaq – honest, direct and laced with the wit that makes you stop and listen. While some might be surprised at his reasoning, the move reflects O'Neal's approach to business: evaluate the data, understand the audience and adjust accordingly. "At first, it was a good investment," he admitted. "But the numbers …" And just like that, the pretzel era of Shaq Inc. was over.
Shaq's business track record includes an impressive portfolio of investments, but not every deal hits the mark. Auntie Anne's, a staple in shopping malls across the country, was one of those ventures that didn't align with his vision. The sale wasn't just about the bottom line but about cultural relevance. O'Neal's willingness to be candid about market realities highlights why he's been able to pivot successfully in his career.
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a>
This isn't the first time Shaq has made a bold call based on cultural insights. During an interview with journalist Graham Bensinger, he reflected on his decision to pass on Starbucks, which he now considers one of his <a href="https://www.outkick.com/culture/shaq-sold-his-17-auntie-annes-franchises-because-black-people-dont-like-pretzels">biggest business regrets</a>. "Howard Schultz wanted to do business with me," he recalled. "But growing up, I'd never seen a Black person drink coffee. I told him, ‘Black people don't drink coffee, sir.' You should've seen his face." Looking back, Shaq sees the missed opportunity as a valuable lesson. "It was a mistake, but I learned from it," he said.
While Auntie Anne's didn't work out, Shaq has found a winning formula in other food ventures. He's a franchisee of Papa John's, owning nine locations and serving on the company's board of directors. His involvement came after the brand's founder, John Schnatter, stepped down following a racial controversy. "For me, it was a great thing to do," O'Neal explained. "The guy just messed up, but he had to pay for that. Now I'm just gonna make sure it's right."
His commitment to Papa John's goes beyond ownership. In addition to helping improve the brand's image, he's worked to lower customer costs and signed an $11 million endorsement deal with the company. "One thing I would never do is sell my people out," Shaq emphasized. "If [Schnatter] was still involved, I wouldn't have touched it."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
O'Neal's decision to walk away from Auntie Anne's shows his ability to read the room – and the spreadsheets. The move wasn't impulsive; it was strategic. He's repeatedly proven that he knows when to stay and when to go, even if it means leaving behind 17 pretzel stands in search of a more promising venture.
With a net worth of <a href="https://www.benzinga.com/markets/24/07/39915962/shaquille-oneal-began-building-his-estimated-500-million-portfolio-by-investing-in-this-tech-titan-w?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate">over $500 million</a>, Shaq's business instincts speak for themselves. Whether it's his early investment in Google or his ongoing partnership with Papa John's, he knows where to put his money – and when to take it out.&nbsp;
For O'Neal, business is as much about understanding people as it is about profit. And if nothing else, his Auntie Anne's exit serves as a reminder that even the best ideas sometimes need a second look. Or, as Shaq would say, "You gotta switch it up."
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

NBA Legend Shaq Owned 17 Auntie Anne's Franchises – But Sold Them After Realizing 'Black people Don't Like Pretzels That Much'

On Thursday, Warner Bros. Discovery, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) stock climbed after the board approved <a href="https://www.benzinga.com/topic/telecom" target="_blank" rel="noreferrer noopener">the company&#8217;s</a> plans to implement a <a href="https://www.benzinga.com/pressreleases/24/12/n42459949/warner-bros-discovery-announces-new-corporate-structure-to-enhance-strategic-flexibility" target="_blank" rel="noreferrer noopener">new corporate structure</a>.
Under this new corporate structure, Warner Bros. Discovery will have two distinct operating divisions: Global Linear Networks and Streaming &amp; Studios.
Global Linear Networks is the linear television business while Streaming &amp; Studios encompasses film and entertainment studios with its intellectual property portfolio. 
Warner Bros. Discovery expects to implement the new corporate structure by mid-2025.
Also Read: <a href="https://www.benzinga.com/24/12/42460647/ciena-q4-earnings-misses-eps-estimates-margins-decline-names-new-chair" target="_blank" rel="noreferrer noopener">Ciena Q4 Earnings: Profit Misses Expectations, Margins Decline, Names New Chair</a>
Earlier this week, Warner Bros. Discovery inked a <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42395322/warner-bros-discovery-stock-soars-after-multi-year-deal-with-comcast-comcast-shares-slide-on-subscriber-loss-estimates" target="_blank" rel="noreferrer noopener">multiyear deal with</a> Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) to provide its content library to Xfinity and Sky customers in the UK and Ireland. The agreement utilizes Comcast&#8217;s global technology platform for linear TV, apps, and streaming services.
In November, Warner Bros. Discovery extended <a target="_blank" href="https://www.benzinga.com/24/11/42044510/warner-bros-stock-jumps-after-securing-11-year-nba-deal-extension" rel="noreferrer noopener">its NBA partnership</a> for eleven years.
Warner Bros. Discovery reported a 3% <a href="https://www.benzinga.com/news/earnings/24/11/41809105/warner-bros-discovery-q3-earnings-olympics-and-blockbusters-drive-gains-ceo-highlights-subscriber-s" target="_blank" rel="noreferrer noopener">third-quarter revenue</a> decline to $9.6 billion, missing the&nbsp;consensus estimate of&nbsp;$9.8 billion.&nbsp;EPS of 5 cents beat the&nbsp;analyst estimate loss of 9 cents.&nbsp;Max added 7.2 million new subscribers in the quarter, marking the platform&#8217;s highest quarterly growth since launch.
Investors can gain exposure to Warner Bros. Discovery through Invesco Leisure and Entertainment ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEJ#NYSE">PEJ</a>) and The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>).
Price Action: Warner Bros. Discovery stock is up 13.7% at $12.30 at the last check Thursday. The stock surged 33% in the last 30 days.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42460099/us-listed-chinese-stocks-give-up-gains-in-anticipation-of-more-stimulus-to-beat-us-tariffs" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Give Up Gains In Anticipation Of More Stimulus</a></li>
</ul>
Image: Shutterstock

CMCSA

PowerShares ETF Leisure & Entertainment Port

Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan

INTS

Intensity Therapeutics shares are trading lower. The company presented final data from Intensity's INVINCIBLE-2 Study and an overview/update of the INVINCIBLE-4 Study.

DA Davidson analyst Gil Luria maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Buy and lowers the price target from $685 to $625.

ADBE

DA Davidson Maintains Buy on Adobe, Lowers Price Target to $625

At the HIV Analyst &amp; Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed that it is developing a once-yearly injectable formulation for lenacapavir.
The annual formulation is currently in Phase 1 study, with data to be presented.
In its investor presentation, the company said it <a target="_blank" href="https://s29.q4cdn.com/585078350/files/doc_events/2024/Dec/10/GILD-HIV-Analyst-Investor-Event-Presentation-10-December-2024.pdf" rel="noreferrer noopener">expects</a> the pivotal Phase 3 pharmacokinetics study&#8217;s first patient to be in 2025, and potential regulatory filings will begin in late 2027.
In September, Gilead revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company&#8217;s twice-yearly injectable HIV-1&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">capsid inhibitor, lenacapavir</a>.
Lenacapavir reduced HIV infections by 96% compared to background HIV incidence.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook</a>
In November, the&nbsp;New England Journal of Medicine&nbsp;published the full results from Gilead&#8217;s Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for HIV prevention.
The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by 96% compared to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42225869/gilead-announces-new-england-journal-of-medicine-publication-of-purpose-2-results" rel="noreferrer noopener">background HIV incidence</a>.
Twice-yearly lenacapavir for PrEP also demonstrated superiority to once-daily Truvada&nbsp;(emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF) for PrEP and was generally well-tolerated, with no significant or new safety concerns identified.
In 2021, the FDA approved ViiV Healthcare&#8217;s Apretude, the first injectable form of PrEP administered every two months.
Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) own ViiV Healthcare.
STAT News <a target="_blank" href="https://www.statnews.com/2024/12/11/hiv-prevention-gilead-once-a-year-prep/?utm_campaign=rss" rel="noreferrer noopener">highlights</a> that Gilead plans to seek approval for a PrEP injection that requires only two clinic visits per year. This less frequent dosing has been shown to be more effective than traditional daily oral PrEP.
However, global access to these new PrEP options remains a challenge. Former CDC director Rochelle Walensky criticized ViiV for not prioritizing accessibility in Africa and urged Gilead to ensure broader availability <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash" rel="noreferrer noopener">of its drug lenacapavir</a>.
Unlike vaccines, which train the immune system to recognize and fight viruses long-term, PrEP relies on antivirals that are effective only while active in the body. The main challenge has been developing drugs that remain effective for extended periods.
While significant progress has been made with long-lasting PrEP, the same cannot be said for HIV vaccines.
Efforts to create a vaccine have struggled against the virus&#8217;s complexity, and no vaccines are currently in late-stage trials following recent setbacks.
The success of long-term PrEP may further complicate vaccine development by reducing the urgency for alternatives.
Price Action: GILD stock is up 0.73% at $93.05 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42467798/why-is-insurance-firm-centene-stock-trading-higher-on-thursday" target="_blank" rel="noreferrer noopener">Why Is Insurance Firm Centene Stock Trading Higher On Thursday?</a></li>
</ul>

Biotech

Large Cap

Health Care

General

GILD

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

AVGO

Broadcom shares are trading lower following a report suggesting Apple's homegrown wireless chip will come to iPhone later in 2025. It was also reported Apple is nearing a switch from Broadcom.

U.S. stocks were lower, with the Nasdaq Composite falling around 0.2% on Thursday.
Shares of Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) rose sharply during Thursday's session after the company reported <a href="https://www.benzinga.com/24/12/42460647/ciena-q4-earnings-misses-eps-estimates-margins-decline-names-new-chair">better-than-expected fourth-quarter sales results.</a>
Ciena reported a fiscal fourth-quarter 2024 revenue decline of 0.5% year-on-year to $1.124 billion, beating the analyst consensus estimate of $1.104 billion.
Ciena shares jumped 14.8% to $84.11 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares jumped 32.4% to $15.23.</li>
<li>Liquidity Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDT#NASDAQ">LQDT</a>) shares climbed 31.6% to $33.88 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) shares gained 25.4% to $8.40.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) surged 21.4% to $1.0461.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) gained 19.5% to $4.0288.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) rose 19.1% to $23.73.</li>
<li>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) gained 17.3% to $15.56 after the company announced it entered into a definitive agreement to acquire Odds Holdings.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) jumped 15.5% to $12.51 after the company announced it authorized a new corporate structure. Also, Guggenheim maintained a Buy rating on the stock and raised its price target from $11 to $12.5.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) gained 15.2% to $6.60.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 11.4% to $29.74 after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $36. Also, Cantor Fitzgerald reiterated an Overweight rating.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) rose 10.2% to $12.97 following a report from The Wall Street Journal indicating activist investor Starboard Value has taken a stake in the company.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) gained 6.7% to $25.19 after Baird raised its price target on the stock from $15 to $32.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

Intraday Update

Movers

BTDR

CIEN

GAMB

HIMX

JUNS

LQDT

RADX

RIOT

Ciena Posts Strong Sales, Joins Gambling.com, Warner Bros. Discovery And Other Big Stocks Moving Higher On Thursday

JP Morgan analyst Cory A Carpenter reiterated the Overweight rating on Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>).
The analyst notes that while Match Group&#8217;s fourth quarter outlook and initial 2025 forecast were disappointing, the company&#8217;s AI-driven roadmap shows potential for reinvigorating user growth, <a target="_blank" href="https://www.benzinga.com/quote/MTCH/analyst-ratings" rel="noreferrer noopener">particularly through Tinder&#8217;s AI features.</a>
However, the analyst points out that AI progress is still early, with only the Photo Selector feature fully implemented.
Despite concerns over Tinder&#8217;s revenue and user trends, Carpenter is more optimistic about Match Group&#8217;s free cash flow potential, which could help limit downside.
Still, improvement in user and revenue metrics for Tinder is necessary for any share price increase, which seems unlikely in 2025.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/12/42439924/match-group-under-pressure-to-deliver-strategy-for-tinders-struggles-and-hinge-growth-at-investor-meeting" rel="noreferrer noopener"> Match Group Faces Investor Scrutiny Over Tinder Woes, Hinge Expansion Plans</a>
The analyst notes that the company revised its revenue expectations downward due to a $15 million FX headwind and stable but lower new user growth on Tinder&#8217;s iOS.
Management remains uncertain about the cause of this decline. Additionally, MTCH maintained its 36% AOI margin forecast for 2024 and paused share repurchases following its investor day, the analyst writes.
Carpenter highlights that Match Group&#8217;s implied dividend yield of 2.4% is significantly higher than other internet companies like Google (0.4%) and Meta Platforms, Inc. (0.3%), which could appeal to value-focused investors.
The analyst anticipates that revenue estimates will be slightly revised downward (to a 6% CAGR, compared to the previous 4-6% guidance), while free cash flow per share estimates for 2027 may be slightly raised ($4.68 vs. the ~$5 guidance).
Price Action: MTCH shares are trading lower by 4% to $30.22 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42466189/trump-talks-stocks-bitcoin-ai-economy-with-jim-cramer-youre-going-to-see-some-very-good-days-ahead" target="_blank" rel="noreferrer noopener">Trump Talks Stocks, Bitcoin, AI, Economy With Jim Cramer: &#8216;You&#8217;re Going To See Some Very Good Days Ahead&#8217;</a></li>
</ul>
Image by Varavin88 via Shutterstock.

Analyst Color

Equities

Reiteration

MTCH

Match Group's Dividend Yield Outshines Peers, But User And Revenue Trends Must Improve For Share Price Boost: Analyst

BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics has announced promising results from their Phase 2 clinical trial, sh...

BriaCell Highlights Promising Breast Cancer Trial Results

BriaCell (BCTX) Therapeutics announces that the Data Safety Monitoring Board has completed its first review of safety events in patients enrolled i...

BriaCell says DSMB recommends continuation of Phase 3 study in MBC

BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics has received approval from the Data Safety Monitoring Board to contin...

BriaCell's Phase 3 Study Progresses in Cancer Fight

BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar fr...

BriaCell Therapeutics: Promising Developments in Cancer Treatment and Positive Outlook

BriaCell Therapeutics announces proposed public offering, shares fall

BriaCell (BCTX) Therapeutics announced that it intends to offer to sell common shares and warrants in an underwritten public offering. All of the c...

BriaCell announces common shares, warrants offering

BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics has announced its plans to sell common shares and warrants in an unde...

BriaCell Therapeutics Plans Public Offering

BriaCell Therapeutics slumps 29%, prices $5.55M stock offering

Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics

ThinkEquity acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving break...

BriaCell 7.4M share Spot Secondary priced at 75c

BCTX

Press Releases

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

Management

BriaCell Provides Update to its Board of Directors

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

Small Cap

Opinion

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

BriaCell Therapeutics Announces Proposed Public Offering

Financing

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

AKYA

BCTXW

CKPT

ONCY

RCUS

TSX:BCT

TSX:ONC

HC Wainwright & Co.

BriaCell Therapeutics shares are trading lower after the company announced the pricing of a $5.5 million public offering of 7.4 million shares at $0.75 per share.

Comments

BriaCell Therapeutics

Noticias

Últimas noticias sobre BriaCell Therapeutics (NASDAQ:BCTX) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL